|
Efficacy of faricimab in the treatment of refractory neovascular age-related macular degeneration
FANG Yiming, SHI Wei, ZHOU Xin, ZHAO Chunlin, ZHANG Siya, WANG Jing, SUN Huaping, PEI Yu, CHEN Xi, PAN Li, JIN Qingzi, TAO Kang, LIN Lin
2025, 39 (7):
674-680.
doi: 10.3969/j.issn.1003-9198.2025.07.006
Objective To evaluate the efficacy of intravitreal injection of faricimab in the patients with refractory neovascular age-related macular degeneration (nAMD). Methods A total of twenty patients with refractory nAMD who had poor responses to previous multiple antivascular endothelial growth factor(VEGF)treatments were enrolled. They received a single intravitreal injection of faricimab in the Ophthalmologic Department of Affiliated Hospital of Nanjing University of Chinese Medicine from April 27 to May 31, 2024. Best corrected vision acuity (BCVA), macular retinal thickness (MRT) which meant the inner limiting membrane to Bruch membrane, central retinal thickness (CST),central choroid thickness (CCT), outer retinal thickness (the outer plexiform layer to Bruch membrane), maximal pigment epithelial detachment (PED) height and area, and neovascularization area (NA) were evaluated before treatment(T1) and 1 week(T2), 1 month(T3), 2 months(T4), and 3 months(T5) after treatment. Results The study included 20 patients (20 eyes). Compared with those before treatment, BCVA and NA were significantly improved 1 week after treatment. BCVA, PED height and NA were significantly improved 1 month after treatment. BCVA, CST, MRT, PED height and NA were significantly improved 2 months after treatment. BCVA, CST, PED height and PED area were significantly improved 3 months after treatment. Additionally, 1 week and 1 month after treatment, CCT showed a positive correlation with PED height and PED area. Conclusions Intravitreal injection of faricimab can effectively improve BCVA, reduce CST and PED height, and decrease PED area in the patients with refractory nAMD.
References |
Related Articles |
Metrics
|